EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia

Brian T Grainger iD, Philip A Thompson iD, Chan Y Cheah iD

Blood · 10.07.2025 · 146 (2) · 145-154

DOI: 10.1182/blood.2024024893 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, erschienen am 10.07.2025. Verfasst von Brian T Grainger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapy with covalent Bruton tyrosine kinase inhibitors (cBTKis) and/or the B-cell lymphoma 2 inhibitor (BCL-2i) venetoclax is now well established in the first-line management of chronic lymphocytic leukemia (CLL). However, patients with “double-refractory” disease due to the acquired resistance to both drug classes represent an increasing clinical challenge for whom few well-tolerated and effective treatment options currently exist. The highly selective, noncovalent BTKi pirtobrutinib and CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel have both recently gained US Food and Drug Administation approval for use in patients with CLL, which has progressed following ≥2 prior lines, including a cBTKi and a BCL-2i. Additionally, novel BTK-directed therapies and T-cell–engaging bispecific antibodies have achieved promising responses in pretreated CLL in early-phase clinical trials. Here, we review the mechanisms responsible for resistance to cBTKi and venetoclax in CLL, appraise recent evidence supporting the use of each of the novel and emerging agent classes, and then suggest innovative treatment strategies incorporating these in patients with double-refractory disease, remaining cognizant of the variability of access to novel therapies and clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellDrug Resistance, NeoplasmProtein Kinase InhibitorsAntineoplastic AgentsHumansAgammaglobulinaemia Tyrosine KinaseBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntibodies, BispecificImmunotherapy, Adoptive

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsvenetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic AgentsBTK protein, humanAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Parkville, VIC, Australia.
  • The Sir Peter MacCallum Department of Clinical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Linear Clinical Research, Nedlands, WA, Australia.
  • University of Western Australia, Nedlands, WA, Australia.

ORCID-Profile: Brian T Grainger, Philip A Thompson, Chan Y Cheah

Zitieren

APA

Grainger, B. T., Thompson, P. A., & Cheah, C. Y. (2025). Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia. Blood, 146(2), 145-154. https://doi.org/10.1182/blood.2024024893

Vancouver

Grainger BT, Thompson PA, Cheah CY. Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia. Blood. 2025;146(2):145-154. doi:10.1182/blood.2024024893

BibTeX
@article{Grainger2025,
  author = {Grainger, Brian T and Thompson, Philip A and Cheah, Chan Y},
  title = {Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia},
  journal = {Blood},
  year = {2025},
  volume = {146},
  number = {2},
  pages = {145--154},
  doi = {10.1182/blood.2024024893}
}
Kostenlos starten →